Volumetric Absorptive Microsampling (VAMS) for Therapeutic Drug Monitoring of Antiseizure Medications (ASMs) in Pediatric Patients
Pharmaceuticals · 29.07.2026 · 19 (8) · 1188
DOI: 10.3390/ph19081188 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 29.07.2026. Verfasst von Raffaele Simeoli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Metabolic Diseases and Hepatology, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, Italian Ministry of Health with “Current Research funds”.
Abstract (Originalsprache)
Background
Volumetric absorptive microsampling (VAMS) is an emerging tool for therapeutic drug monitoring (TDM) of several drugs including antiseizure medications (ASMs). Here, we compared the concentrations of carbamazepine (CBZ), levetiracetam (LEV), lacosamide (LCS), topiramate (TPR) and the benzodiazepine (BZ) clobazam (CLB) in plasma and VAMS samples.
Methods
VAMS samples were collected by fingerprick in pediatric patients followed at our center. Patients were also subjected to conventional venous blood sampling. Plasma and VAMS samples were analyzed by using a UHPLC-MS/MS validated kit for AEs and BZs (ClinMass LC-MS/MS Complete Kit®). A cross-validation analysis was performed by using Spearman correlation (rho), Deming regression and Bland–Altman plots.
Results
Two analytical methods for measuring selected AEs and BZs in VAMS samples were developed and validated in accordance with the ICH M10 guidelines. Based on Bland–Altman results, a satisfactory agreement was observed between VAMS and plasma for CBZ, LCS, TPR, LEV and N-CLB. Considering the absence of interchangeability between capillary blood and plasma levels for CBZ-Diol, -Epoxi and CLB, a blood to plasma ratio was used to convert VAMS values into estimated plasma concentrations. Comparison of estimated vs. observed plasma results showed a successful predictive performance for this conversion approach.
Conclusions
A positive agreement between plasma and VAMS was found for CBZ, LCS, TPR, LEV and N-CLB. Conversely, a conversion factor based on blood to plasma ratio should be adopted to convert CBZ-Diol, -Epoxi and CLB VAMS results into estimated plasma concentrations. This study confirmed the utility of VAMS for TDM of selected ASMs in pediatric patients during routine clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Metabolic Diseases and Hepatology, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy.
- Neurology, Epilepsy, and Movement Disorders Unit, Full Member of European Reference Network EpiCARE, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy.
ORCID-Profile: Raffaele Simeoli, Alessandro Mancini, Sara Cairoli, Chiara Rossi, Carlo Dionisi Vici, Nicola Pietrafusa, Nicola Specchio
Förderung
- Italian Ministry of Health
- Italian Ministry of Health with “Current Research funds”
Zitieren
APA
Simeoli, R., Mancini, A., Cairoli, S., Rossi, C., Calabrese, C., Trivisano, M., Salimbene, L., Dionisi Vici, C., Pietrafusa, N., Specchio, N., & Goffredo, B. M. (2026). Volumetric Absorptive Microsampling (VAMS) for Therapeutic Drug Monitoring of Antiseizure Medications (ASMs) in Pediatric Patients. Pharmaceuticals, 19(8), 1188. https://doi.org/10.3390/ph19081188
Vancouver
Simeoli R, Mancini A, Cairoli S, Rossi C, Calabrese C, Trivisano M, et al. Volumetric Absorptive Microsampling (VAMS) for Therapeutic Drug Monitoring of Antiseizure Medications (ASMs) in Pediatric Patients. Pharmaceuticals. 2026;19(8):1188. doi:10.3390/ph19081188
BibTeX
@article{Simeoli2026,
author = {Simeoli, Raffaele and Mancini, Alessandro and Cairoli, Sara and Rossi, Chiara and Calabrese, Costanza and Trivisano, Marina and Salimbene, Licia and Dionisi Vici, Carlo and Pietrafusa, Nicola and Specchio, Nicola and Goffredo, Bianca Maria},
title = {Volumetric Absorptive Microsampling (VAMS) for Therapeutic Drug Monitoring of Antiseizure Medications (ASMs) in Pediatric Patients},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {8},
pages = {1188},
doi = {10.3390/ph19081188}
}
EUVIMED